U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C18H33ClN2O5S.ClH
Molecular Weight 461.444
Optical Activity UNSPECIFIED
Defined Stereocenters 9 / 9
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CLINDAMYCIN HYDROCHLORIDE

SMILES

Cl.CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@H](C)Cl)[C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O

InChI

InChIKey=AUODDLQVRAJAJM-XJQDNNTCSA-N
InChI=1S/C18H33ClN2O5S.ClH/c1-5-6-10-7-11(21(3)8-10)17(25)20-12(9(2)19)16-14(23)13(22)15(24)18(26-16)27-4;/h9-16,18,22-24H,5-8H2,1-4H3,(H,20,25);1H/t9-,10+,11-,12+,13-,14+,15+,16+,18+;/m0./s1

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C18H33ClN2O5S
Molecular Weight 424.983
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry
Defined Stereocenters 9 / 9
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Clindamycin phosphate is the prodrug of clindamycin with no antimicrobial activity in vitro but can be rapidly converted in vivo to the parent drug, clindamycin, by phosphatase ester hydrolysis. It is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes; Skin and skin structure infections; Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes; Intra-abdominal infections; Septicemia; Bone and joint infections. Orally and parenterally administered clindamycin has been associated with severe colitis, which may end fatally. Abdominal pain, gastrointestinal disturbances, gram-negative folliculitis, eye pain and contact dermatitis have also been reported in association with the use of topical formulations of clindamycin. Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents

CNS Activity

Originator

Approval Year

TargetsConditions
PubMed

PubMed

TitleDatePubMed
Superantigen antagonist peptides.
2001
Lemierre's syndrome with spondylitis and pulmonary and gluteal abscesses associated with Mycoplasma pneumoniae pneumonia.
2001 Apr
Clinical features of patients with invasive Eikenella corrodens infections and microbiological characteristics of the causative isolates.
2001 Apr
Individualized pharmacokinetic monitoring results in less aminoglycoside-associated nephrotoxicity and fewer associated costs.
2001 Apr
Activation of clindamycin phosphate by human skin.
2001 Apr
[The latest trend of PRSP infection].
2001 Apr
Severe babesiosis in Long Island: review of 34 cases and their complications.
2001 Apr 15
Phenotypic and genotypic characterization of antibiotic-resistant Propionibacterium acnes isolated from acne patients attending dermatology clinics in Europe, the U.S.A., Japan and Australia.
2001 Feb
A combination benzoyl peroxide and clindamycin topical gel compared with benzoyl peroxide, clindamycin phosphate, and vehicle in the treatment of acne vulgaris.
2001 Feb
Dermatopharmacology of a new combination gel formulation for the topical treatment of acne.
2001 Feb
Are 2 combined antimicrobial mechanisms better than 1 for the treatment of acne vulgaris? Clinical and antimicrobial results of a topical combination product containing 1% clindamycin and 5% benzoyl peroxide. Introduction.
2001 Feb
Potential role for a new combination topical therapy in treating mild to moderate acne vulgaris.
2001 Feb
The development of antibiotic resistance in Propionibacterium acnes.
2001 Feb
Therapeutic studies with a new combination benzoyl peroxide/clindamycin topical gel in acne vulgaris.
2001 Feb
Anti-anaerobic activity of antibacterial agents.
2001 Feb
Incidence of beta-lactamase production and antimicrobial susceptibility of anaerobic gram-negative rods isolated from pus specimens of orofacial odontogenic infections.
2001 Feb
Two cases of diskitis attributable to anaerobic bacteria in children.
2001 Feb
Antimicrobial resistance of Streptococcus pneumoniae isolates in 1999 and 2000 in Madrid, Spain: a multicentre surveillance study.
2001 Feb
Antibiotic susceptibility of Kingella kingae isolates from respiratory carriers and patients with invasive infections.
2001 Feb
Clostridium difficile--Associated diarrhea: A review.
2001 Feb 26
Folliculitis decalvans.
2001 Jan
Clonal relationships among penicillin-susceptible, multiresistant serotype 6B Streptococcus pneumoniae isolates recovered in Greece and France.
2001 Jan
Emerging erythromycin resistance among group B streptococci in Korea.
2001 Jan
[Prevention of endocarditis within the scope of ENT interventions. Current recommendations].
2001 Jan
Puerperal sepsis: a disease of the past?
2001 Jan
Clostridium difficile colitis following antibiotic prophylaxis for dental procedures.
2001 Jan
Two cases of severe bronchopneumonia due to influenza A (H3N2) virus: detection of influenza virus gene using reverse transcription polymerase chain reaction.
2001 Jan
New uses of older antibiotics.
2001 Jan
A rare case of primary group A streptococcal peritonitis.
2001 Jul
Elution characteristics of vancomycin, teicoplanin, gentamicin and clindamycin from calcium sulphate beads.
2001 Jul
[Chronic osteomyelitis of the ilium after autologous bone harvesting in Albers-Schonberg osteopetrosis. A case report].
2001 Jun
Infection of hamsters with epidemiologically important strains of Clostridium difficile.
2001 Jun 15
[The therapeutic approach to necrotizing fasciitis].
2001 Mar
[Cellulitis and necrotizing fasciitis: microbiology and pathogenesis].
2001 Mar
Antimicrobial susceptibilities of Erysipelothrix rhusiopathiae isolated from pigs with swine erysipelas in Japan, 1988-1998.
2001 Mar
Antibiotic-resistant bacteria in pediatric chronic sinusitis.
2001 Mar
Detection and characterization of a bacteriocin, garviecin L1-5, produced by Lactococcus garvieae isolated from raw cow's milk.
2001 Mar
Antibiotic resistance rates and macrolide resistance phenotypes of viridans group streptococci from the oropharynx of healthy Greek children.
2001 Mar
Tufted hair folliculitis after scalp injury.
2001 Mar
Treatment of nosocomial postoperative pneumonia in cancer patients: a prospective randomized study.
2001 Mar
Sequential parapharyngeal abscesses.
2001 Mar
Phenotypic and genotypic characterization of macrolide-resistant group A Streptococcus strains in the province of Quebec, Canada.
2001 Mar
Molecular epidemiology and genetic linkage of macrolide and aminoglycoside resistance in Staphylococcus intermedius of canine origin.
2001 Mar 20
[Dermo-hypodermitis and necrotizing fasciitis].
2001 Mar 31
The treatment of babesiosis.
2001 Mar 8
Clinical inquiries. What are the most effective treatments for bacterial vaginosis in nonpregnant women?
2001 May
High prevalence of carriage of antibiotic-resistant Streptococcus pneumoniae in children in Kampala Uganda.
2001 May
When to suspect and how to monitor babesiosis.
2001 May 15
Multi-laboratory assessment of the linezolid spectrum of activity using the Kirby-Bauer disk diffusion method: Report of the Zyvox Antimicrobial Potency Study (ZAPS) in the United States.
2001 May-Jun
Prevalence of serotypes and molecular epidemiology of Streptococcus pneumoniae strains isolated from children in Beijing, China: identification of two novel multiply-resistant clones.
2001 Spring
Patents

Sample Use Guides

In Vivo Use Guide
150 to 300 mg every 6 hours (Serious infections), 300 to 450 mg every 6 hours (More severe infections), 8 to 16 mg/kg/day divided into three or four equal doses (Serious infections in pediatric patients), 16 to 20 mg/kg/day divided into three or four equal doses (More severe infections in pediatric patients).
Route of Administration: Topical; Vaginal; Intramuscular; Intravenous
In Vitro Use Guide
MIC=0.03-0.12 ug/ml (Aerobic Pathogens), MIC=0.06-0.25 ug/ml (Anaerobes).
Substance Class Chemical
Created
by admin
on Tue Oct 22 00:37:02 UTC 2019
Edited
by admin
on Tue Oct 22 00:37:02 UTC 2019
Record UNII
T20OQ1YN1W
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CLINDAMYCIN HYDROCHLORIDE
EP   GREEN BOOK   MART.   MI   ORANGE BOOK   USP   VANDF   WHO-DD  
Common Name English
ANTIROBE
Brand Name English
SOBELIN
Brand Name English
CLINDAMYCIN HCL
Common Name English
CLINDAMYCIN HYDROCHLORIDE [GREEN BOOK]
Common Name English
CLINDAMYCIN HYDROCHLORIDE [WHO-DD]
Common Name English
DALACIN C
Brand Name English
L-THREO-.ALPHA.-D-GALACTO-OCTOPYRANOSIDE, METHYL 7-CHLORO-6,7,8-TRIDEOXY-6-(((1-METHYL-4-PROPYL-2-PYRROLIDINYL)CARBONYL)AMINO)-1-THIO-,(2S-TRANS)-, MONOHYDROCHLORIDE
Common Name English
CLINDAMYCIN HYDROCHLORIDE [VANDF]
Common Name English
CLINSOL
Brand Name English
CLINTABS
Brand Name English
CLINDAMYCIN HYDROCHLORIDE [USP]
Common Name English
CLINDAMYCIN HYDROCHLORIDE [ORANGE BOOK]
Common Name English
CLINDAMYCIN HYDROCHLORIDE [MI]
Common Name English
CLINDAMYCIN HYDROCHLORIDE [MART.]
Common Name English
CLINDAMYCIN HYDROCHLORIDE [JAN]
Common Name English
CLINDAMYCIN (AS HYDROCHLORIDE)
Common Name English
CLINDAMYCIN HYDROCHLORIDE ANHYDROUS
Common Name English
METHYL 7-CHLORO-6,7,8-TRIDEOXY-6-(1-METHYL-TRANS-4-PROPYL-L-2-PYRROLIDINECARBOXAMIDO)-1-THIO-L-THREO-.ALPHA.-D-GALACTO-OCTOPYRANOSIDE MONOHYDROCHLORIDE
Common Name English
CLINDAMYCIN HYDROCHLORIDE [EP]
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 213405
Created by admin on Tue Oct 22 00:37:02 UTC 2019 , Edited by admin on Tue Oct 22 00:37:02 UTC 2019
NCI_THESAURUS C82922
Created by admin on Tue Oct 22 00:37:02 UTC 2019 , Edited by admin on Tue Oct 22 00:37:02 UTC 2019
Code System Code Type Description
CAS
21462-39-5
Created by admin on Tue Oct 22 00:37:02 UTC 2019 , Edited by admin on Tue Oct 22 00:37:02 UTC 2019
PRIMARY
NCI_THESAURUS
C47977
Created by admin on Tue Oct 22 00:37:02 UTC 2019 , Edited by admin on Tue Oct 22 00:37:02 UTC 2019
PRIMARY
EVMPD
SUB127118
Created by admin on Tue Oct 22 00:37:02 UTC 2019 , Edited by admin on Tue Oct 22 00:37:02 UTC 2019
PRIMARY
PUBCHEM
16051951
Created by admin on Tue Oct 22 00:37:02 UTC 2019 , Edited by admin on Tue Oct 22 00:37:02 UTC 2019
PRIMARY
ChEMBL
CHEMBL1753
Created by admin on Tue Oct 22 00:37:02 UTC 2019 , Edited by admin on Tue Oct 22 00:37:02 UTC 2019
PRIMARY
ECHA (EC/EINECS)
244-398-6
Created by admin on Tue Oct 22 00:37:02 UTC 2019 , Edited by admin on Tue Oct 22 00:37:02 UTC 2019
PRIMARY
RXCUI
81982
Created by admin on Tue Oct 22 00:37:02 UTC 2019 , Edited by admin on Tue Oct 22 00:37:02 UTC 2019
PRIMARY RxNorm
EVMPD
SUB01342MIG
Created by admin on Tue Oct 22 00:37:02 UTC 2019 , Edited by admin on Tue Oct 22 00:37:02 UTC 2019
PRIMARY
MERCK INDEX
M3624
Created by admin on Tue Oct 22 00:37:02 UTC 2019 , Edited by admin on Tue Oct 22 00:37:02 UTC 2019
PRIMARY Merck Index
EPA CompTox
21462-39-5
Created by admin on Tue Oct 22 00:37:02 UTC 2019 , Edited by admin on Tue Oct 22 00:37:02 UTC 2019
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
IMPURITY -> PARENT
Related Record Type Details
ACTIVE MOIETY